Acute Kidney Injury (AKI) adversely impacts 25% of critically ill children and can be hard to identify with serum creatinine alone. ProNephro AKI™ (NGAL) is the first FDA-cleared test for assessing AKI risk in ICU patients aged 3 months to 22 years. A low NGAL result indicates a low risk of AKI, allowing for confident use of interventions such as fluids, diuretics, or nephrotoxic medications. Elevated NGAL values signal a high risk of developing AKI, triggering nephrology consults and interventions 2-3 days before serum creatinine rises.Visit booth 1342 to learn how ProNephro AKI (NGAL) can improve AKI management in your patients and get an update on our adult clinical trial. https://bioporto.us/pronephro-aki/
BioProduction by SEKISUI
BioProduction by Sekisui offers CDMO services for the biopharmaceutical industry. Our UK facility has over 40 years fermentation and purification experience with proteins. Our microbial expression and process optimization together with our production experience helps smooth technical transfer and process scale up. We have process and analytical development capabilities for enzymes, plasmids, antibody fragments and other proteins. We are completing a $19M cGMP manufacturing expansion for drug substance manufacturing in 2024. We are co-exhibiting with Sekisui America Corporation, the regional HQ of global chemical manufacturer Sekisui Chemical, located in the United States. They work on developing solutions for the life science industry, with a focus on cell and gene therapy. Products include cell culture consumables such as state-of-the-art cell culture media and scaffolds. Chemically defined scaffold (CDS) can be used for the serum-free culture of pluripotent stem cells (iPSCs, ESCs, MSCs and so on). It is a synthetic polymer that can be stored at room temperature, pre-coated on a variety of surfaces and can be adapted to automated culture equipment. It can establish a safe and stable cell culture process and can lead to reduction in total cell culture cost. We are looking for partners in the field of cell and gene therapy such as academic organizations, pharmaceutical companies and automated bioreactor manufacturers who can act as joint development partners in adapting our products for their pipeline. | BioProduction by SEKISUI – A Specialized CDMO within the SEKISUI Medical Group BioProduction by SEKISUI is the biomanufacturing CDMO division of SEKISUI Diagnostics, part of the globally recognized SEKISUI Medical Group.BioProduction by SEKISUI describes SEKISUI’s contract service offering as a microbial fermentation focused CDMO with over 40 years of expertise in microbial biomanufacturing. We specialize in microbial fermentation, protein purification, and downstream processing for enzymes, recombinant proteins, ligands, antibody fragments, and plasmids. With experience in E. coli, Pichia pastoris, Bacillus, Streptococcus, Streptomyces, fungi, and yeast, we provide seamless process transfer and scale-up to meet diverse biopharmaceutical needs. Our UK-based facility features fermentation capacities ranging from 2L to 5,000L, advanced chromatography techniques, and lyophilization capabilities. While cGMP capacity expansion for clinical-grade drug substance manufacturing is in progress, we adhere to ISO 9001 standards, ISO 8 cleanroom classifications, and environmental safety regulations, ensuring quality and reliability. Driven by Kaizen-based continuous improvement and a zero-emissions sustainability commitment, BioProduction by SEKISUI partners with global leaders to deliver scalable, high-quality biomanufacturing solutions. Learn more at bioproduction-sekisui.com. SEKISUI CHEMICAL Group has been driving innovation since 1947. Today, we’re committed to developing cell culture solutions that make cell culture more reliable, scalable, and efficient. Our flagship product, Ceglu™, is a chemically defined, synthetic matrix that provides a stable, feeder-free environment for stem cells (iPSCs, ESCs, MSCs). Designed for consistency and ease of use, Ceglu™ reduces variability and offers the convenience of room-temperature storage. Ceglu™ is available in two formats: pre-coated culture plates for immediate use and a coating solution that can be applied to automated culture systems and bioreactors for seamless large-scale production. With a focus on advancing regenerative medicine, SEKISUI collaborates with industry leaders to deliver innovative solutions that meet the evolving needs of the cell and gene therapy field and help achieve shared goals. Learn more at https://www.sekisui-cell.jp/en/
Biopôle SA
Biopôle Lausanne is one of the largest life sciences campus in Europe, hosting a vibrant community of world-renowned industry players and research institutes, based in Lausanne, Switzerland (www.biopole.ch). It offers a world-class combination of modern infrastructure (134,000 sqm of office/lab space), added value services, an extensive network, innovation and funding programmes, and unparalleled community engagement where members can thrive and bring science to life. Biopôle houses 130+ life sciences companies, including 50 biotech/pharma such as Ferring, Roche, Ichnos, etc. and world-class research organizations (Lausanne University Hospital (CHUV), University of Lausanne (UNIL), the Ludwig Institute for Cancer Research etc.), a life science incubator (StartLab), ready-to-move-in private labs (Superlab), a Digital Health Hub (DH2) enabling the emergence of outstanding innovation for the betterment of healthcare. Join Biopôle.
BIOPOP International Inc
BIOPOP International Inc. revolutionizes health monitoring with its ELIXIR device, a non-invasive, real-time blood analysis tool. Using near-infrared (NIR) spectroscopy, ELIXIR captures detailed biochemical data through the skin. This cutting-edge technology, combined with a user-friendly mobile app, offers users comprehensive insights in
Bionics Research Center
FluxiHeal is a smart therapeutic patch developed by the Bionics Research Center at KIST. It combines microfluidics, hydrogel, and iontophoresis to manage wound exudate and deliver regenerative drugs non-invasively.
BiomimX
BiomimX S.r.l. is a pioneer in proposing the next generation of clinically relevant in–vitro models: human, dynamic, 3D. BiomimX offers high-content, controlled and reliable in vitro setups (Beating Organs on Chip) to achieve a deeper insight on human biology, pivotal for the effective discovery of new therapies. Every tissue in the body is subjected to motion: Beating Organs on Chip provide controlled mechanical stimulation to 3D cell culture, developing more reliable, fast responsive, and predictive in vitro physiological or pathological models to profile, expand and explore new therapies for complex diseases. BiomimX’s portfolio comprises among other organs, uHeart, uKnee, uScar, uGut, Liver-Heart, uLung. | BiomimX S.r.l. is a pioneer in Organ on a Chip (OoC) technology, producing the next generation of clinically relevant in-vitro models for pharmaceutical drug discovery and testing. Our proprietary platform integrates microfluidics, 3D cell culture, live human cells, and mechanical stimuli to produce “Beating Organs on a Chip” . These recapitulate, with unprecedented precision and predictability, clinically relevant models reflective of human physiology and pathology. Pharma R&D is an area where animal models continue to fall short due to lack of translatability and/or lack of relevant models. Regulatory agencies in the US and Europe are now moving forward to encourage biopharma’s use of more predictive non-animal models. BiomimX is poised to be a leader in this space and has gained early traction with industry. Every tissue in the body is subject to motion. The advantage of BiomimX approach is our patented uBeat platform which provides 3D microtissues with controlled mechanical stimulation. Current competitors are limited to 2D cultures without mechanical stimulation and poor scalability. Our models overcome this with 3D culture, mechanical stimulation, and materials allowing for enhanced scalability. This provides a window into human organs and complex disease, without involving animals. The result is a more reliable, responsive, and predictive in vitro model to investigate new therapies. BiomimX lead model is uHeart (Visone, Tox Sciences, 2023; +4 additional cardiac publications), a functional beating heart on a chip for cardiotoxicity and safety testing early in the pipeline. uHeart was recently qualified with 12 drugs as a predictor of functional cardiotoxicity, showing 83.3% sensitivity, 100% specificity, and 91.6% accuracy. Our pipeline includes a range of predictive physiological and pathological models. uKnee (Occhetta, Nature Biomed Eng, 2019; +2 additional OA publications) has successfully supported a recent IND. Other key models include uScar (fibrosis; Visone, Adv Health Mat, 2023), uGut (Ballerini, Nature Biomed Eng, 2025), uLung and uLiver-Heart (Ferrari, Adv Mat Tech, 2023). The company’s founders have deep expertise in microfluidics, microtechnology, translational science, and advanced 3D in-vitro cell culture technologies. Founding members also serve in academia and notable leadership roles for key societies in the field, including Chair and Board Member of the European Organ on Chip Society. In addition, they are currently communicating with the Innovation Task Force (ITF) of EMA regarding BiomimX models. They have over 20+ publications in the field and a strong track record of EU grant success aimed at forwarding the field of OoC. The company is revenue producing with global biopharma and CROs as clients and aims to revolutionize the way new drugs are tested.
BioLife Solutions
BioLife Solutions is a leading developer, manufacturer and supplier of class-defining cell and gene therapy bioproduction tools and services. Our solutions facilitate basic and applied research and commercialization of new therapies by maintaining the health of biologic source material and finished products during manufacturing, storage and distribution.